FDA Acceptance of NDA220381 from Fresenius Kabi USA
The FDA has accepted the New Drug Application (NDA) 220381 from Fresenius Kabi USA for review.
Published: August 1, 2026
Updated: August 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Not specified
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
The FDA's acceptance of NDA220381 for review signifies a critical step for Fresenius Kabi USA, potentially leading to market entry. This development may alter competitive dynamics, necessitating strategic adjustments from other players in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for the FDA review process and any announcements regarding approval or further requirements.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.